EW

Edwards Lifesciences is a high-quality structural heart franchise, anchored by TAVR leadership and a growing transcatheter mitral/tricuspid therapies (TMTT) platform that can extend its growth runway beyond aortic valves. Q4 2025 TAVR sales grew ~12% to $1.16B, signaling durable procedure demand despite competitive pressure, while newer systems (including EVOQUE) support expansion in undertreated patient populations. The key strategic question is how quickly TMTT can scale to offset maturation in core TAVR in some geographies.

Financially, Edwards remains solidly profitable with strong balance sheet flexibility, supported by ~17.7% profit margin, ROA ~7.7%, ROE ~10.4%, ~$4.23B cash and low leverage (debt/equity ~6.8%), based on available trailing metrics. Trailing revenue is roughly $6.1B, and market cap in early April 2026 appears to be about $46B, implying a premium valuation that requires consistent mid-to-high single digit growth and margin execution. Management guided to 2026 constant-currency sales growth of 8–10% and adjusted EPS of $2.90–$3.05, which sets a relatively high bar if procedure growth slows or competition intensifies.

Over the next 12 months, the thesis is that steady TAVR execution plus accelerating TMTT adoption can sustain an above-market growth profile, but multiple risk is meaningful. Catalysts include quarterly proof points that TMTT is scaling (and mix is improving), and any positive clinical/regulatory milestones that broaden eligible patients; risks include international pricing/competition and any slip versus the 2026 EPS range. DIY investors should watch TAVR procedure growth commentary, TMTT revenue trajectory, and margin progression versus management’s guidance.

Recommendation: HOLD. The upside hinges on TMTT scaling fast enough to justify a premium valuation, while the downside risk is that any growth or margin disappointment could compress the multiple even if the business remains fundamentally strong.